A cost-effectiveness model for coronary thrombolysis/reperfusion therapy

• Published in: Journal of the American College of Cardiology Vol. 10; no. 5; pp. 79B - 90B
• Main Authors: Laffel, Glenn L., Fineberg, Harvey V., Braunwald, Eugene
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.11.1987
• Subjects: Angioplasty, Balloon - economics; Coronary Angiography; Coronary Disease - economics; Coronary Thrombosis - economics; Coronary Thrombosis - mortality; Coronary Thrombosis - therapy; Coronary Vessels; Cost-Benefit Analysis; Decision Trees; Drug Evaluation; Humans; Models, Theoretical; Myocardial Infarction - economics; Myocardial Infarction - mortality; Myocardial Infarction - therapy; Recurrence; Risk Factors; Stroke Volume - drug effects; Time Factors
• ISSN: 0735-1097; 1558-3597
• DOI: 10.1016/S0735-1097(87)80432-1

A model was designed to examine the relations between incremental costs and benefits of coronary thrombolysis/reperfusion therapy. The model allows for the study of intravenous and intracoronary streptokinase, intravenous tissue plasminogen activator and primary angioplasty. Three strategies for the management of reocclusion are also compared. It was found that each of the following four variables can be responsible for a 2- to 15-fold variation in the costs per additional survivor: 1) the quantity of jeopardized myocardium, 2) the duration of coronary occlusion before the onset of therapy, 3) the time required from the onset of therapy until reperfusion is achieved, and 4) the reocclusion management strategy. Therapeutic strategies involving intravenous administration of thrombolytic agents were found to be consistently more cost effective than were strategies involving intracoronary administration of thrombolytic agents and primary angioplasty. In patients with a large or moderate-sized infarct, proper selection of intravenous protocols and reocclusion management strategies leads to costs of $7,000 to $100,000/additional survivor, costs that are similar to those of many generally accepted medical practices. Substantially higher costs per additional survivor are incurred with the routine use of thrombolytic therapy in patients with a small infarct or the routine use of coronary artery bypass surgery to reduce the risk of reocclusion after successful thrombolytic therapy. Decisions regarding which patients should receive thrombolysis/reperfusion therapy depend on society's willingness to pay for its incremental benefits.